Imfinzi in combination with chemotherapy has been recommended for approval in the European Union for the treatment of ...
Goldman Sachs analysts added AstraZeneca (AZN) to the firm’s European Conviction List as part of its monthly update. With 28 Phase-3 readouts ...
Cambridge: AstraZeneca and Daiichi Sankyo's Enhertu (trastuzumab deruxtecan) has been recommended for approval in the ...
Investment analysts at Zacks Research dropped their Q3 2025 earnings per share (EPS) estimates for shares of AstraZeneca in a report issued on Thursday, February 27th. Zacks Research analyst R.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results